![Martin C. Münchbach](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martin C. Münchbach
Directeur/Membre du Conseil chez
YPSOMED HOLDING AG
Fortune : 180 896 $ au 30/06/2026
Profil
Martin C.
Münchbach currently works at Tioga Pharmaceuticals, Inc., as Director from 2005, Ypsomed Holding AG, as Independent Non-Executive Director from 2019, BioVascular, Inc., as Director, binx health, inc., as Director, BB Biotech Ventures, as Managing Director from 2004, Binx Health Ltd., as Director from 2011, Alentis Therapeutics AG, as Director, Ariceum Therapeutics GmbH, as Non-Executive Director from 2021, BB Biotech Ventures GP Ltd., as Partner, Bellevue Asset Management (Venture Capital), as Senior Investment Advisor from 2009, and Pureos Partners AG, as Managing Partner from 2017.
Dr. Münchbach also formerly worked at Radius Health, Inc., as Independent Director from 2012 to 2015, Optimer Pharmaceuticals LLC, as Director from 2005 to 2008, Molecular Partners AG, as Director, Opsona Therapeutics Ltd., as Director, Sonetik AG, as Director, Sanofi-Synthélabo SA, as Head-Marketing, New Medical Technologies AG, as Investment Manager from 2000 to 2003, and BioMedInvest AG I, as Partner.
Dr. Münchbach received his graduate degree and doctorate degree from Swiss Federal Institute of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 400 ( 0% ) | 180 896 $ | 30/06/2026 |
Postes actifs de Martin C. Münchbach
| Sociétés | Poste | Début |
|---|---|---|
| YPSOMED HOLDING AG | Directeur/Membre du Conseil | 01/01/2019 |
Binx Health Ltd.
 Binx Health Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research and development on biotechnology | Directeur/Membre du Conseil | 19/07/2011 |
Pureos Partners AG
 Pureos Partners AG Investment ManagersFinance Pureos Partners invests in companies located in Switzerland. The firm focuses on drug development companies. It participates in early stage capital transactions. | Private Equity Investor | 01/01/2017 |
Alentis Therapeutics AG
 Alentis Therapeutics AG BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapies to treat cancer and reverse fibrosis | Directeur/Membre du Conseil | - |
BB Biotech Ventures | Directeur Général | 01/01/2004 |
Biotech Ventures GP Ltd.
 Biotech Ventures GP Ltd. Financial ConglomeratesFinance Venture capital fund | Corporate Officer/Principal | - |
binx health, inc.
 binx health, inc. Medical SpecialtiesHealth Technology Develops point-of-care test solutions for chlamydia and gonorrhea & related software solutions | Directeur/Membre du Conseil | - |
Tioga Pharmaceuticals, Inc.
 Tioga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for the treatment of gastrointestinal diseases | Directeur/Membre du Conseil | 01/01/2005 |
Bellevue Asset Management (Venture Capital)
 Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is an active manager which invests primarily in private companies developing and marketing drugs and medical devices or providing healthcare services. The investment focus is on the US and Europe. The firm typically invests USD 7-15 million over an investee companies' lifetime, seeking to invest in companies with entrepreneurial individuals/teams, the ability to attain milestones in a timely manner, an advanced clinical pipeline, a proven technology base, good commercialization potential, growing markets, a medical need, significant competitive advantages, barriers to entry and a clear path to liquidity. It generally co-invests in syndicates with other venture capital firms, both leading the syndicate and acting as an active co-investor. It normally seeks representation on the boards of their portfolio companies, partnering with management to create value. The firm typically holds an investment for three to five years. | Private Equity Investor | 01/01/2004 |
| ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Anciens postes connus de Martin C. Münchbach
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░ ░░░░ ░░░ ░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Martin C. Münchbach
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
64
Relations au 1er degré
20
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 20 |
|---|---|
Sanofi-Synthélabo SA
 Sanofi-Synthélabo SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for cardiovascular treatment, central nervous system, internal medicine drugs and oncology treatment | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes bone health and related therapeutics | Health Technology |
Tioga Pharmaceuticals, Inc.
Tioga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for the treatment of gastrointestinal diseases | Health Technology |
New Medical Technologies AG
 New Medical Technologies AG Investment ManagersFinance Acts as an alternative investment manager | Finance |
Ypsomed Holding AG
 Ypsomed Holding AG Medical SpecialtiesHealth Technology Manufactures injections and diagnostic devices | Health Technology |
Optimer Pharmaceuticals LLC
 Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes anti-infective products | Health Technology |
Swiss Federal Institute of Technology
 Swiss Federal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioMedInvest AG I
 BioMedInvest AG I Investment ManagersFinance Acts as Venture Capital Fund | Finance |
Biotech Ventures GP Ltd.
Biotech Ventures GP Ltd. Financial ConglomeratesFinance Venture capital fund | Finance |
BioVascular, Inc.
 BioVascular, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs and devices for control of intimal hyperplasia associated with vascular procedures | Health Technology |
Molecular Partners AG
 Molecular Partners AG BiotechnologyHealth Technology Engages in discovery, development and commercialization of biopharmaceutical products | Health Technology |
binx health, inc.
binx health, inc. Medical SpecialtiesHealth Technology Develops point-of-care test solutions for chlamydia and gonorrhea & related software solutions | Health Technology |
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Provides immunology drug for treatment of inflammatory diseases | Health Technology |
Bellevue Asset Management (Venture Capital)
Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is an active manager which invests primarily in private companies developing and marketing drugs and medical devices or providing healthcare services. The investment focus is on the US and Europe. The firm typically invests USD 7-15 million over an investee companies' lifetime, seeking to invest in companies with entrepreneurial individuals/teams, the ability to attain milestones in a timely manner, an advanced clinical pipeline, a proven technology base, good commercialization potential, growing markets, a medical need, significant competitive advantages, barriers to entry and a clear path to liquidity. It generally co-invests in syndicates with other venture capital firms, both leading the syndicate and acting as an active co-investor. It normally seeks representation on the boards of their portfolio companies, partnering with management to create value. The firm typically holds an investment for three to five years. | Finance |
Sonetik AG
 Sonetik AG Medical SpecialtiesHealth Technology Manufactures and markets hearing aid solutions | Health Technology |
BB Biotech Ventures | |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners invests in companies located in Switzerland. The firm focuses on drug development companies. It participates in early stage capital transactions. | Finance |
Binx Health Ltd.
Binx Health Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research and development on biotechnology | Commercial Services |
Alentis Therapeutics AG
Alentis Therapeutics AG BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapies to treat cancer and reverse fibrosis | Health Technology |
Ariceum Therapeutics GmbH
 Ariceum Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Develops novel targeted radiopharmaceuticals for treatment of cancer | Health Technology |
